Table 1.
Baseline patient characteristics
| Characteristic | Value (n=303) |
|---|---|
| Recipient age (years) | 56 (34–73) |
| Sex, male:female | 247:56 |
| Donor age (years) | 34 (11–71) |
| Preoperative AFP level (ng/mL) | 59.8±210.6 |
| MELD score | 12.7±7.2 |
| Child-Pugh class, A:B:C | 166:96:41 |
| Etiology of HCC | |
| HBV | 238 (78.5) |
| HCV | 24 (7.9) |
| Alcohol-related | 27 (8.9) |
| NBNC | 14 (4.6) |
| Type of graft | |
| LDLT | 216 (71.3) |
| DDLT | 87 (28.7) |
| ABO incompatible | 47 (15.5) |
| Number of tumors | 3.6±4.6 |
| Maximum tumor size (cm) | 2.5±1.9 |
| Microscopic vascular invasion | 79 (26.1) |
| Immunosuppression regimen | |
| CNI alone or CNI plus MMF | 189 (62.4) |
| CNI plus everolimus | 114 (37.6) |
| Exceeding Milan criteria | 77 (25.4) |
| Recurrence | 49 (16.2) |
| Follow-up duration (months) | 37.1 (1.2–80.2) |
Values are presented as mean±standard deviation, median (range), or number (%) unless otherwise indicated.
AFP, alpha-fetoprotein; MELD, model for end-stage liver disease; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-B, non-C; LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation; CNI, calcineurin inhibitor; MMF, mycophenolate mofetil.